Pregabalin
Inquiry
| Post Date: | Jan 09,2018 |
| Expiry Date: | Jul 08,2018 |
| Detailed Description: |
Cas No. :148553-50-8
Quantity: mass in stockKilograms Specs:white powder Price:negotiable USD Kilograms Payment Method: T/T, Western Union,Moneygram and Bitcoin. Description: Pregabalin, marketed under the brand name Lyrica among others, is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its use for epilepsy is as an add-on therapy for partial seizures with or without secondary generalization in adults. Some off-label uses of pregabalin include restless leg syndrome, prevention of migraines, social anxiety disorder, and alcohol withdrawal.When used before surgery it does not appear to affect pain after surgery but may decrease the use of opioids. Common side effects include: sleepiness, confusion, trouble with memory, poor motor coordination, dry mouth, problem with vision, and weight gain.Potentially serious side effects include angioedema, drug misuse, and an increased suicide risk. When pregabalin is taken at high doses over a long period of time, addiction may occur, but if taken at usual doses the risk of addiction is low.Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Medical uses Seizures Pregabalin is useful when added to other treatments, when those other treatments are not controlling partial epilepsy. Its use alone is less effective than some other seizure medications. It is unclear how it compares to gabapentin for this use. Neuropathic pain The European Federation of Neurological Societies recommends pregabalin as a first line agent for the treatment of pain associated with diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain. A minority obtain substantial benefit, and a larger number obtain moderate benefit. Other first line agents, including gabapentin and tricyclic antidepressants, are given equal weight as first line agents, and unlike pregabalin, are available as less expensive generics. Pregabalin is not recommended for certain other types of neuropathic pain such as trigeminal neuralgia and its use in cancer-associated neuropathic pain is controversial. There is no evidence for its use in the prevention of migraines and gabapentin has been found not to be useful. It has been examined for the prevention of post-surgical chronic pain, but its utility for this purpose is controversial. Pregabalin is generally not regarded as efficacious in the treatment of acute pain. In trials examining the utility of pregabalin for the treatment of acute post-surgical pain, no effect on overall pain levels was observed, but people did require less morphine and had fewer opioid-related side effects. Several possible mechanisms for pain improvement have been discussed. Anxiety disorders The World Federation of Biological Psychiatry recommends pregabalin as one of several first line agents for the treatment of generalized anxiety disorder, but recommends other agents such as SSRIs as first line treatment for obsessive-compulsive disorder and post-traumatic stress disorder. It appears to have anxiolytic effects similar to benzodiazepines with less risk of dependence. The effects of pregabalin appear after 1 week of use and is similar in effectiveness to lorazepam, alprazolam, and venlafaxine, but pregabalin has demonstrated superiority by producing more consistent therapeutic effects for psychosomatic anxiety symptoms. Long-term trials have shown continued effectiveness without the development of tolerance, and, in addition, unlike benzodiazepines, it has a beneficial effect on sleep and sleep architecture, characterized by the enhancement of slow-wave sleep. It produces less severe cognitive and psychomotor impairment compared to those drugs; it also has a low potential for abuse and dependence and may be preferred over the benzodiazepines for these reasons. |
| CAS Registry Number: | 148553-50-8 |
| Synonyms: | ;3-(aminomethyl)-5-methyl-hexanoic acid;Pregablin;(3S)-3-(aminomethyl)-5-methyl-hexanoic acid;(R-)-3-isobutyl GABA;3-isobutyl GABA;CI 1008;CI-1008;3-(aminomethyl)-5-methyl-(3S)-Hexanoic acid;3-(aminomethyl)-5-methyl-(S)-Lyrica;PD 144723;PD-144723;Pregabalin [USAN];TOS-BB-0910;Pregabalin intermediate;(3R)-3-(aminomethyl)-5-methylhexanoic acid;(S)-Pregabalin;(S)(+)-3-Aminomethyl-5-methyl-hecanoic acid; |
| Molecular Formula: | C8H17NO2 |
| Molecular Weight: | 159.2261 |
| Molecular Structure: | 
|
| Company: | Hengyang Desen Biotechnology Co., Ltd. [ China ] |
| Contact: | ava |
| Tel: | 86-18908446905 |
| Fax: | |
| Email: | ava@ycgmp.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
